Latanoprost + timolol

Reactive airway disease (e.g. existing or history of bronchial asthma, severe COPD); sinus bradycardia, sick sinus syndrome, sino-atrial block, 2nd- or 3rd-degree atrioventricular block (not controlled with a pacemaker), overt cardiac failure, cardiogenic shock; active herpes simplex keratitis or history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.

Patients with history of atopy or severe anaphylaxis to allergens, 1st-degree heart block, heart failure, orthostatic hypotension, severe peripheral circulatory disturbance or disorders (e.g. severe forms of Raynaud's syndrome), mild or moderate COPD, diabetes (especially labile diabetes), hyperthyroidism, corneal diseases, other types of glaucoma (e.g. inflammatory, neovascular or chronic angle-closure glaucoma, open-angle glaucoma of pseudophakic patients, pigmentary glaucoma), closed-angle glaucoma (as monotherapy), history of herpetic keratitis, active intraocular inflammation; aphakic patients, pseudophakic patients with torn posterior lens capsule, risk factors for macular oedema; myasthenia gravis. Patients undergoing surgery. Patient Counselling Remove contact lenses before administration and reinsert after 15 minutes. This drug may cause transient blurring of vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor intraocular pressure, changes in iris colour and eyelash; systemic effects of β blockade; signs and symptoms of heart failure.

Significant: Choroidal detachment (post-filtration procedures), increased iris pigmentation, eyelid skin and eyelash changes (increased length, darkening and thickening of the eyelashes), anaphylactic reactions, bacterial keratitis, macular oedema (e.g. cystoid macular oedema). Eye disorders: Eye pain or irritation (e.g. stinging, burning, itching, foreign body sensation), blepharitis, blurred vision, corneal disorder, conjunctivitis, eye hyperaemia. Nervous system disorders: Dizziness, headache. Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Cardiac failure; bronchospasm (in patients with asthma).

May have potentiated effects on intraocular pressure or systemic β-blockade with oral or other topical β-adrenergic blockers. Latanoprost: Paradoxical increase in intraocular pressure with another prostaglandin analogues. Timolol: May have additive effects resulting in hypotension and/or notable bradycardia with oral Ca channel blockers, guanethidine, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, narcotics and MAOIs. Potentiated systemic β blockade (e.g. decreased heart rate, depression) with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine). May result in mydriasis with epinephrine. May potentiate the hypertensive reaction to sudden withdrawal of clonidine. May increase the hypoglycaemic effect of anti-diabetic agents.

Antiglaucoma Preparations

S01EE01 - latanoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
S01ED01 - timolol ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
C07AA06 - timolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases.